---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-102552"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:40:22.572851+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Invivyd announces PEMGARDA neutralizing activity against dominant variants KP.3.1.1 and LB.1

## Summary
- New in vitro data show PEMGARDA neutralizes KP.3.1.1 (42.2% of US cases) and LB.1 variants.
- Pemivibart epitope intact across 99.59% of viral sequences since Omicron BA.1.
- Data submitted to FDA for timely updates to PEMGARDA Fact Sheet.
- Pipeline candidate VYD2311 also shows potent neutralization against contemporary variants.
- Company notes 33 variants tested over two years; addresses preliminary non-peer-reviewed reports questioning activity.

## SEC filing metadata
- accession: 0000950170-24-102552
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017024102552/0000950170-24-102552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017024102552/ivvd-20240903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-102552
- JSON: https://secwatch.observer/filing/0000950170-24-102552.json
- Plain text: https://secwatch.observer/filing/0000950170-24-102552.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.